Rao et al. (63) evaluated the possibility of HDAC inhibitors valproic acid and suberoylanilide hydroxamic acid to enhance the activity of first-line anti-TB drugs to inhibit the growth of intracellular M. tuberculosis. This evidence concerns the gene HDAC9 and tuberculosis.